Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at firstname.lastname@example.org. Follow @suzannewriter on Twitter.
- Contact Suzanne
- Follow Suzanne on Google+
Articles by Suzanne Elvidge
While vaccines against Streptococcus pneumoniae have cut the number of deaths from this bug that can cause pneumonia and meningitis, the number of cases has tripled in the past 50 years.
Researchers in Canada are touting a 2009 swine flu shot as a potential route to a universal vaccine that could target all forms of influenza, according to data published in Frontiers of Immunology.
Immunomic Therapeutics is developing a DNA plasmid-based allergy vax for this allergy, code-named JRC-LAMP-vax, and has been cleared by the U.S. FDA to begin a Phase I clinical trial in Atlanta in June 2012.
A team from Australia has shown positive immune responses in a Phase II trial of Pfizer's meningitis B vaccine in teenagers.
Hemispherx Biopharma's RNA-based adjuvant, Ampligen (rintatolimod), is being tested in a new indication--this time intranasally for the first time in humans along with AstraZeneca's nasal flu vaccine FluMist.
Preclinical data published in Vaccine on Dutch biotech Mucosis' nasal flu vaccine showed that it protected mice against infection with the flu virus.
Novavax saw a climb in its share value on the announcement that it has started enrollment of a Phase I clinical trial of its A/H5N1 vaccine to prevent bird flu.
Researchers at the Moffitt Cancer Center are developing "designer" lymph nodes that could be used to boost the effects of cancer vaccines.
Japan has granted marketing approval for its first inactivated polio vaccine (IPV), Sanofi's Imovax Polio, and will begin using the vaccine in public immunization programs beginning Sept. 1.
GlaxoSmithKline's meningitis vaccine Nimenrix has been granted approval in Europe by the Committee for Medicinal Products for Human Use (CHMP).